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Abstract
Background: Dengue is an important mosquito-borne viral infection that affects millions of persons worldwide.
Early diagnosis is necessary to effect appropriate management and decrease mortality. Immunochromatographic tests
are advantageous in producing dengue test results within 30 min but these results should be sensitive and specific. In
this study we evaluated the diagnostic performance of the SD BIOLINE Dengue DUO® rapid immunochromatographic
test kit. A panel of 309 dengue and 30 non-dengue single serum samples characterized by using reference
enzyme-linked immunosorbent assays (ELISAs) was used. These samples were received in the virology laboratory
for routine testing during a dengue type 1 outbreak between October to December, 2012.
Results: The overall diagnostic sensitivities of the SD BIOLINE Dengue DUO® rapid testfor IgM, IgG and NSI were
49.3 % (95 % CI: 41.3-57.4), 39.1 % (95 % CI: 33.3-45.2) and 90 % (95 % CI: 82.1-94.7), respectively. The IgM and
IgG detection rates were significantly lower than that of the NSI (p < 0.001). However the combination of the
IgM detection with NS1 detection or both NS1 and IgG resulted in a significant (p < 0.001) increase in sensitivity
to 97.5 % (95 % CI: 92.9-99.2) and 98.9 % (95 % CI: 96.0-99.7), respectively. These higher sensitivities were achieved
without any decrease in specificities.
Conclusions: This study revealed that combining two or more parameters of the SD BIOLINE Dengue DUO®
rapid kit significantly improved the sensitivity of diagnosis of dengue virus infection and supports its usefulness
in the Jamaican setting.
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Background
Dengue is a viral infection caused by the dengue virus
(DENV). DENV is a member of the Flaviviridae family
of ribonucleic acid (RNA) viruses which also includes
West Nile virus (WNV), Yellow fever virus (YFV) and
Japanese encephalitis (JE) virus [1, 2]. There are four se-
rotypes of dengue virus (DENV-1, DENV-2, DENV-3
and DENV-4) although recently a possible fifth serotype
(DENV-5) was reported [3]. The virus is arthropod
borne and is transmitted to humans by the bite of an in-
fected female mosquito. The primary vector is the Aedes
aegypti mosquito but other species such as Aedes albo-
pictus and less commonly Aedes polynesiensis can also
transmit the virus [4, 5]. Dengue occurs in tropical and
subtropical regions of the world with endemicity in over
100 countries including Jamaica [2, 6–8]. Although den-
gue is endemic in the Americas, outbreaks generally
recur with a 3 to 5 year cycle [8]. The last epidemic in
Jamaica was in the year of 2012 and was caused by
DENV-1 [9, 10].
The clinical manifestations of dengue usually follow an
incubation period of 2–7 days and may include a wide
variety of signs and symptoms [11]. According to the
most recent classification by the World Health
Organization (WHO) persons are classified as having
dengue with or without warning signs or severe dengue
[12]. The criteria for dengue without warning signs in-
clude fever and two of nausea and vomiting, rash, aches
and pains, leucopenia and a positive tourniquet test.
Warning signs include abdominal pain or tenderness,
persistent vomiting, mucosal bleeding, among others.
There is no vaccine or specific treatment for dengue but
early diagnosis and supportive management can decrease
the mortality of severe dengue disease [13].
The laboratory diagnosis of dengue includes virus iso-
lation, serological and molecular techniques [5, 12, 14].
Viral isolation is generally time-consuming while mo-
lecular methods are expensive. Enzyme-linked immuno-
sorbent assay (ELISA) is most often used in the
diagnosis of dengue in Jamaica and other countries.
These tests detect dengue specific antibodies such as im-
munoglobulin (Ig)-M, IgG, IgA or dengue antigens par-
ticularly non-structural (NS)-1 glycoproteins [15, 16].
More recently, rapid immunochromatographic tests
(ICTs) have become available. The diagnostic perfor-
mances of the dengue ICT kits have been noted to vary
with different countries. We, therefore, sought to deter-
mine the performance characteristics of a rapid dengue
ICT kit in Jamaica.
Methods
Study site
The study was conducted at the virology laboratory in
the Department of Microbiology of the University
Hospital of the West Indies (UHWI), a tertiary referral
hospital, after ethical approval was obtained (ECP 181,
12/13). The virology laboratory is the reference labora-
tory for testing dengue virus in Jamaica and receives
specimens from all 14 parishes of the island.
Study design
A retrospective cross sectional design was used to screen
archived single serum samples received in the virology la-
boratory with a request for dengue IgM antibody testing
between October and December 2012. All samples were
stored at −70 °C after routine diagnostic testing until in-
cluded in this study for evaluation. The inclusion criteria
for the sample selection were: presence of the date of onset
of symptoms, presence of the date of collection of specimen
and sufficient sample volume. A total of 339 of the 3402 ar-
chived single serum samples met the inclusion criteria and
were selected. Demographic and clinical information were
extracted from the hospital records.
Dengue diagnostic tests
The dengue NS1 antigen ELISA (Standard Diagnostics Inc.,
Seoul, Korea) and the dengue IgM and IgG antibody cap-
ture ELISAs (Focus Diagnostics, Cypress, PA, USA) were
used as the reference methods [16–18]. All reference test-
ing procedures were performed and interpreted according
to the manufacturers’ instructions except for the interpret-
ation of the IgM assay. The IgM ELISA was interpreted
as: − positive: index value ≥1.2; negative: index value <1.0;
equivocal: index value >1.0 and <1.2. Samples (n = 28) that
were repeatedly equivocal were excluded from analysis. The
manufacturer’s instructions for the SD BIOLINE Dengue
DUO® (SDB DD) NS1 Ag and IgG/IgM ICT were followed
and are described previously [19]. Briefly, 100 μl and 10 μl
of serum specimen were added to the sample well “S” of
the NS1 Ag and IgM/IgG strips of the combo device, re-
spectively. Four drops of assay diluents were added to the
assay diluent well of the latter. Both strips of the device
were read at 15–20 min.
Classification of samples
The samples were classified as dengue, non-dengue, pri-
mary, secondary, acute or convalescent. A sample was
defined as dengue if it was positive for at least one of
dengue IgM, IgG or NS1 antigen biomarker and non-
dengue if negative for all three biomarkers. A primary
dengue sample was one in which the IgM/IgG optical
density (OD) ratio is ≥1.2. If the ratio was <1.2 it was
designated as secondary [12, 20, 21]. Sample collection
time was expressed in days(s) post onset of symptoms
(DPO) and was interpreted with day 1 being the first
24 h. An acute sample was one with a DPO ≤ 5 days
while a convalescent sample was defined as having a
DPO > 5 days. The combination strategies for the SDB
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DD ICT are as described before [22]. An IgM/NS1 com-
bination result meant dengue if either IgM or NS1 was
positive and non-dengue if both were negative irrespect-
ive of the IgG result. The IgM/NS1/IgG combination
result was interpreted as dengue if at least one of SD
IgM, IgG or NS1 was positive and non-dengue if all
three were negative.
Statistical analysis
Microsoft Excel (Microsoft Inc., Redmond, Washington,
USA) was used for data entry and data analysis was done
using Epi info 7 (Centers for Disease Control and Prevention,
Atlanta, USA). Chi-square test and the Fisher’s exact test
(two sided) were used to compare categorical variables. A
probability value (p) of < 0.05 was considered statistically
significant. The sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV) and kappa




The 339 consecutively archived samples selected for the
evaluation were obtained from 159 (47 %) female and
180 (53 %) males. The median age was 13 years (range,
10 days to 95 years) and the median time between the
onset of illness and collection of specimens was 4 days
(range, 1 to 22 days). The samples were characterized
using the reference ELISAs for dengue IgM, IgG and
NS1 antigen and classified initially as 309 (91 %) dengue
and 30 (9 %) non-dengue. The 309 dengue samples were
further defined by dengue phase as 189 (61 %) acute,
120 (39 %) convalescent and by immune status as 80
(26 %) primary and 229 (74 %) secondary.
Overall diagnostic performance
The diagnostic performance of the individual assay
parameters in comparison to the reference standard
ELISAs is shown in Table 1. The overall diagnostic
sensitivities of the SDB DD rapid test for IgM, IgG, and
NS1 were 49.3 % (95 % CI: 41.3-57.4), 39.1 % (95 % CI
33.3-45.2) and 90 % (95 % CI: 82.1-94.7), respectively.
The IgM and IgG detection rates were significantly
lower than that of the NS1 (p < 0.001). However, the
combination of the IgM detection with NS1 detection
or both NS1 and IgG resulted in a significant
(p < 0.001) increase in sensitivity to 97.5 % (95 % CI:
92.9-99.2) and 98.9 % (95 % CI: 96.0-99.7), respectively.
These higher sensitivities were achieved with increase
specificities of 100 %. The kappa coefficients for the
NS1, IgM/NS1 and IgM/NS1/IgG parameters were 0.91
(95 % CI: 0.81-1.0), 0.97 (95 % CI: 0.86-1.0), and 0.96
(95 % CI: 0.83-1.0), respectively.
The IgG test had the lowest sensitivity of 39.1 %
(95 % CI: 33.3-45.2) but the highest individual specifi-
city of 100 % (95 % CI: 95.6-100). It also demon-
strated a very high individual positive predictive value
(PPV) of 100 % (95 % CI: 95.6-100) but a very low
negative predictive value (NPV) of 34.7 % (95 % CI:
29.0-41.0). The PPV and NPV for the NS1 compo-
nent, the combined IgM/NS1 and IgM/NS1/IgG were
all high.
Sensitivity of SDB DD tests according to primary and
secondary dengue immune status
Figure 1 shows that the IgM detection was signifi-
cantly higher in samples with primary dengue (72.6 %;
95 % CI: 60.4-82.1 %) than secondary dengue (31.7 %;
95 % CI: 22.7-42.4) infection (p < 0.001). Although the
sensitivities of the NS1 and IgG markers were lower
in secondary dengue samples (88.2 % and 52.1 %,
respectively), than in primary (91.1 % and 63.0 %,
respectively), the differences were not significant.
There was a slight non-significant increase in the sen-
sitivities of the IgM/NS1 and IgM/NS1/IgG combined
dengue biomarkers in secondary dengue samples
(98 %; 95 % CI: 89.5-99.7 and 98.6 %; 95 % CI: 92.9-
99.8, respectively), over primary dengue samples
(97.1 %; 95 % CI: 90.2-99.2 and 98.6 %; 95 % CI: 92.3-
99.0, respectively).
Table 1 Overall diagnostic performance of the SDB DD ICT against reference ELISAs
Dengue Parameter No. of dengue
ELISA
pos/neg











IgM 145/194 71/187 49.3 (41.3-57.4) 95.9 (92.1-97.9) 89.9 (81.3-94.8) 71.9 (66.2-77.0)
NS1 90/249 81/247 90.0 (82.1-94.7) 99.2 (97.1-99.8) 97.6 (91.6-99.3) 96.5 (93.5-98.1)
IgG 256/83 100/83 39.1 (33.3-45.2) 100 (95.6-100) 100 (96.3-100) 34.7 (29.0-41.0)
IgM/NS1 121/157 117/157 97.5 (92.9-99.2) 100 (97.6-100) 100 (96.8-100) 98.1 (94.6-99.4)
IgM/ NS1/ IgG 181/29 179/29 98.9 (96.0-99.7) 100 (88.3-100) 100 (97.9-100) 93.6 (79.3-98.2)
95 % CI is shown in parenthesis. pos = positive; neg = negative; SDB DD = SD BIOLINE Dengue DUO®; ICT = Immunochromatographic test
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Sensitivity of SDB DD tests according to acute and
convalescent phases
The IgM was significantly more sensitive (p < 0.001) in
convalescent serum samples (67.2 %; 95 % CI: 55.3-77.2)
as compared to acute samples (33.8 %; 95 % CI: 24.2-
44.9) (Fig. 2). In contrast, the sensitivity of the IgG, NS1,
and the combined strategies of IgM/NS1 and IgM/NS1/
IgG were not significantly affected by acute or convales-
cent dengue phases.
Sensitivity of SDB DD NS1 test according to IgM/IgG
antibody profiles
In this study, the presence of IgM and/or IgG did not
significantly impact the sensitivities of the SDB DD NS1
tests although the sensitivities generally trend higher in
the absence of IgM/IgG (Table 2). The sensitivities of
the SDB DD dengue biomarkers were not affected by
age or sex.
Discussion
The NS1 test component of the SDB DD ICT kit had
the highest individual sensitivity of 90 % when compared
to the reference ELISA for the diagnosis of dengue in
Jamaica. Slightly lower but similarly high sensitivities
(81.6 % and 87.5 %) were also reported by Gan et al. in
Singapore [25] and by Sanchez-Vargas et al. in Mexico
[26], respectively. In both of those studies the authors
used a different NS1 ELISA (Platelia™) as comparator.
In contrast, others have reported markedly lower SDB
DD NS1 sensitivity findings in the range of 44-51 % [22,
27, 28]. The lower sensitivities were attributed to the
possible presence of high IgG antibody titres in those
samples. It was hypothesized that dengue viral antigens,
inclusive of NS1, may form immune complexes with
high levels of dengue IgG antibodies and thus become
undetectable [29, 30]. High titres of IgG are more likely
to be found in secondary dengue infections. Andries
et al. [28], for example, found significant reduction of
NS1 sensitivity in secondary infection (43.4 %) when
compared to primary infection (89.5 %) (p < 0.001).
While the sensitivity of the SDB DD NS1 in this study
was generally lower in the presence of measurable IgG
antibodies this was not statistically significant. Similarly,
although we found a lower NS1 sensitivity in secondary
infections than in primary infections, this again was not
significant. Our results, however, are not unique and
similar findings were reported by Gan et al. and
Sanchez-Vargas et al. [25, 26].
It appears therefore that although IgG antibody titres
may have some impact on the NS1 sensitivity levels, this
alone may not explain the low sensitivity levels obtained
in some studies [22, 27, 28]. Perhaps, other factors including
the type of reference method used in the comparisons
were contributing to the observed trends. Those studies
with low NS1 sensitivities all used non-NS1 comparators
such as virus isolation and genome detection by poly-
merase chain reaction (PCR) as the reference standards
[22, 27, 28]. Hang et al. and Tricou et al. in their evaluations
of the relationship between NS1 sensitivity to viraemia
using several NS1 assays have shown that NS1 levels
correlate with viraemia [30, 31]. They have also found
that NS1 negative patients had significantly lower mean
viraemia than NS1 positive patients. Although the cor-


























Primary  dengue samples (n=80) Secondary dengue samples (n=229)
*
Fig. 1 Sensitivity of SDB DD ICT according to dengue immune status. Data represent sensitivity (%) and error bars represent 95 % CI. *indicates
significance at p < 0.001, when comparing primary and secondary dengue samples
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precise, we are of the opinion that studies which use
virus isolation or genome detection methods may be de-
tecting lower levels of viraemia in those samples which,
in effect, are less likely to be NS1 positive.
The fact that the SD NS1 sensitivity, in our study, was
high and was not significantly affected by factors such as
primary/secondary infection status, acute/convalescent
and the presence/absence of IgM/IgG antibodies is def-
initely advantageous. Accordingly, this test is ideal for
use in dengue endemic as well as non-endemic coun-
tries. It would also be extremely helpful in making den-
gue diagnosis in areas where patients present in either
the acute (≤5 days) and early convalescent (>5 days)
phases of dengue illness.
The overall sensitivity of the SDB DD IgM compo-
nent alone was low and is consistent with a
previously published report of a sensitivity of 47 %
and 49.7 % in Puerto Rico and Malaysia, respectively
[17]. Clinicians should, therefore, not use a negative
IgM result alone to rule out dengue infection in
these settings. The SDB DD dengue IgM test param-
eter was significantly lower in acute and secondary
dengue samples. These are expected findings which
demonstrate the dynamics of the host IgM immune
response [29, 32]. IgM is therefore considered more
a marker of recent infection rather than of acute in-
fection [29] and so this limits its usefulness when
used alone as a single biomarker in the diagnosis of
dengue infection.
The limitations of the SDB DD IgM biomarker alone,
however, disappeared when it was combined with other
dengue biomarkers. Herein lies the advantage of the
SDB DD kit in that it has the capacity to measure both
dengue antigen and dengue antibodies in one test. This
allows for different testing strategies. We explored differ-
ent combination approaches with the IgM/IgG and NS1
biomarkers and found that combining any two or more
of the individual components resulted in even greater
levels of diagnostic sensitivities. Our data provides evi-
dence, in keeping with others who have recently re-
ported, that using a combination strategy enhances the
overall diagnostic performance of rapid dengue diagnos-
tic kits [19, 25–28, 33]. For example, Wang et al. [19] re-
ported improvement in sensitivity from 53.5 % (IgM







IgM−/IgG− 94.4(74.2- 99.0) 18 0.899a
IgM+/IgG− 91.2(77.0-97.0) 34
IgM−/IgG+ 100(75.8-100) 12 0.265b
IgM+/IgG+ 80.8(62.1-91.5) 26
95 % CI is shown in parenthesis; − = negative; + = positive; a = comparison



























Acute dengue samples (n=189) Convalescent dengue samples (n=120)
*
Fig. 2 Sensitivity of SDB DD ICT according to sample collection phase. Data represent sensitivity (%) and error bars represent 95 % CI. *indicates
significance at the p < 0.001 level when comparing acute and convalescent dengue samples
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alone) to 88.7 % (NS1/IgM) while Sanchez-Vargas et al.
[26] found enhanced sensitivity from 60.51 % (IgM
alone) to 90.65 % (NS1/IgM/IgG). It should be noted
that in both of the above mentioned studies the im-
provement in sensitivities came with slight decrease in
specificities unlike our study in which there were slight
increase in specificities to 100 %. This pattern of im-
provement in test performance by combination of mul-
tiple dengue biomarkers is not only observed for SDB
DD ICT kits but also for other rapid dengue diagnostic
kits [25, 33]. Additionally, in the current study, the
sensitivity of the combination of the NS1/IgM/IgG bio-
markers was not significantly affected by dengue im-
mune and phase status which is in agreement with
others [25, 28].
There are some limitations in the current study.
Firstly, the study samples were not specifically tested for
other flaviviruses nor for other diseases such as malaria
and leptospirosis, and therefore it is not known what
level of cross reactivities were present. It would have
been interesting to demonstrate the effect, if any, of
West Nile virus (WNV) infection on the specificities of
the SDB DD ICT kit since a previous study by Brown
et al. (unpublished data) among dengue suspected cases
in Jamaica showed that 5.9 % (26/435) had cross reactive
antibodies to WNV.
Secondly, there could be misclassification bias due to:
(1) use of single serum samples which would not be able
to demonstrate dengue seroconversion as may occur
with paired samples and (2) use of serological tests alone
instead of more sensitive methods of detection e.g. PCR.
Further studies are recommended to investigate the ef-
fect of disease severity, other viral serotypes and com-
parative molecular testing methods on the performance
of the SDB DD ICT kit in Jamaica.
Conclusions
In summary, this evaluation showed that the NSI compo-
nent of the SDB DD ICT kit is very sensitive and specific
for the diagnosis of dengue infections irrespective of sam-
ples being acute/convalescent or primary/secondary.
Combining the IgM parameter with detection of either
NS1 alone or both NS1 and IgG significantly improved its
sensitivity without decreasing the specificity. The SDB DD
ICT kit is therefore a very useful tool for the diagnosis of
dengue.
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